CompletedPhase 2NCT04667910

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Principal Investigator
Xiao rong Li, MD
TianJing Medical University Eye Hospital
Intervention
601 1.25mg(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20212022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04667910 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials